Metformin, one of the most frequently prescribed medications for type 2 diabetes, reportedly exerts BP-lowering effects in patients with diabetes. However, the effects and underlying mechanisms of metformin on BP in non-diabetic conditions remain to be determined. The aim of the present study was to determine the effects of metformin on angiotensin II (Ang II) infusion-induced hypertension in vivo.
Introduction
The widely used oral hypoglycaemic agent metformin (dimethylbiguanide) is a current first-line treatment for type 2 diabetes (Pawlyk et al., 2014) and decreases hyperglycaemia (Hundal et al., 2000) , body weight (Seifarth et al., 2013) , hyperinsulinaemia (Kolodziejczyk et al., 2000) and cancer cell growth (Morales and Morris, 2015) . Importantly, metformin was reported to markedly decrease BP in experimental rats (Verma et al., 1994a,b; Bhalla et al., 1996; Muntzel et al., 1997) and patients (Landin-Wilhelmsen, 1992; Uehara et al., 2001) . For example, metformin blunted salt-induced hypertension (Muntzel et al., 1999) and prevented hypertension in spontaneously hypertensive rats (Tsai et al., 2014) . Metformin treatment, however, failed to decrease BP in obese non-diabetic patients with hypertension, in comparison with placebo (He et al., 2012) and in spontaneously hypertensive rats (Santure et al., 2000) . In addition, metformin exerts only a minor, clinically insignificant, effect on BP in non-diabetic hypertensives (Snorgaard et al., 1997) . Thus, the anti-hypertension effects of this hypoglycaemic agent are highly variable, depending upon the animal models or types of patients examined. The factors and/or molecular mechanisms that determine the responsiveness of blood vessels to BP-lowering effects of metformin remain uncharacterized.
The activation of the renin-angiotensin-aldosterone system (RAAS) is established as a contributor to the pathogenesis of hypertension (Takahashi et al., 2011) . Angiotensin II (Ang II) is thought to play a key role in regulating BP as well as water and sodium balance (Benigni et al., 2010) . Furthermore, Ang II activates sympathetic nerve activity and arteriolar vasoconstriction, increases sodium and water retention and stimulates antidiuretic hormone secretion in the pituitary gland to increase water reabsorption in the collecting duct (Carey, 2015) , ultimately resulting in elevated BP. Blockers of renin, angiotensin-converting enzyme, Ang II AT 1 receptors and aldosterone, all components of the RAAS, provide clinically useful, hypertension-reducing treatments (Te Riet et al., 2015) . Recently, AT 2 receptor activation by compound 21, a highly selective non-peptide agonist, prevented sodium retention and lowered BP in Ang II-dependent hypertensive rats (Kemp et al., 2016) . However, some discrepancies between these results and the real clinical outcomes of treatment remain, suggesting that other mechanisms by which Ang II may regulate the progression of hypertension could be important. Furthermore, endoplasmic reticulum (ER) stress in the brain subfornical organ was reported to contribute to Ang IIdependent hypertension (Young et al., 2012) . Our previous studies have shown that aberrant ER stress in vascular smooth muscle cells (VSMCs) enhances vascular contractility, resulting in high BP in mice (Liang et al., 2013) . Thus, ER stress in VSMCs plays an essential role in the initiation and progression of Ang II-induced hypertension.
AMP-activated protein kinase (AMPK) is a central regulator of cellular metabolism and redox balance in mammalian tissues (Song and Zou, 2012) . The vascular AMPK complex consists of three subunits, the α, β and γ subunits (Song and Zou, 2012) . AMPKα2 deficiency causes aberrant ER stress in endothelial cells, resulting in endothelial dysfunction and accelerated atherogenesis in Western dietfed apolipoprotein E knockout mice (Dong et al., 2010a) . AMPK activation inhibits LDL-triggered ER stress in endothelium in vitro and in mice in vivo (Dong et al., 2010b) . Moreover, AMPKα2 deletion leads to aberrant ER stress in VSMCs and subsequent high BP (Liang et al., 2013) , confirming the notion that AMPKα2 and its physiological suppression of ER stress are essential for maintaining normal vascular tone.
Published work from us and others indicates that metformin exerts its therapeutic effects by activating AMPK (Zheng et al., 2013; Cho et al., 2015) . Metformin represses palmitate-induced ER stress in rat insulinoma cells (SimonSzabo et al., 2014) , and also restores endothelial function in high-fat diet-induced obese mice, via blunting of ER stress (Cheang et al., 2014) . AMPK inhibition results in excessive ER stress in carotid arteries of spontaneously hypertensive rats , whereas AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) paeonol, or berberine, suppresses ER stress in mouse aortas and rat carotid arteries (Liang et al., 2013; Liu et al., 2015; Choy et al., 2016) . Based on our current understanding of Ang II infusion-induced hypertension, we sought to determine whether AMPK-suppressed ER stress is required for the BP-lowering effects of metformin. Here, we report that Ang II-induced aberrant ER stress in VSMCs contributes to the elevation of BP and that metformin acts via AMPKα2 activation-induced suppression of ER stress in VSMCs to lower Ang II-induced high BP in mice.
Methods

Animals
All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of Georgia State University. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Mice deficient in AMPKα1 (AMPKα1 À/À ) or AMPKα2 (AMPKα2 À/À ) were generated as described by Jorgensen et al., (2004) . Wild-type (WT) C57BL/6J, AMPKα1
and AMPKα2
À/À mice (aged 10-12 weeks) +were anaesthetized and then implanted with osmotic minipumps containing Ang II or vehicle under the skin on the backs of the mice, as described previously (Wu et al., 2015) . The mice were continuously infused with Ang II (0.8 μg·g À1 ·day À1 , 14 days) or vehicle (saline). On the same day, half of the mice were treated with metformin (300 mg·kg À1 body weight per day in drinking water) or AICAR (500 mg·kg À1 body weight, one i.p. injection per day for 14 days, saline as vehicle). BP was measured using both the carotid catheter method and the radiotelemetry technique described previously (Liang et al., 2013) . Mice were housed in temperature-controlled cages under a 12 h light-dark cycle and given free access to water and a regular rodent diet.
(100 U·mL
À1
) and streptomycin (100 μg·mL
). All cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. Cells were grown to 70-80% confluence before being treated with the different agents.
Western blot analysis
Cell lysates were subjected to Western blot analysis as described previously (Song et al., 2009) . The protein content was assayed using the BCA protein assay reagent (Pierce Chemical Co., Rockford, IL, USA). Proteins (20 μg) were separated by SDS-PAGE and then transferred to a membrane. The membrane was incubated with a 1:1000 dilution of primary antibody, followed by a 1:5000 dilution of horseradish peroxidase-conjugated secondary antibody. Protein bands were visualized with enhanced chemiluminescence (ECL) (Pierce Chemical Co.).
Immunohistochemistry
The mouse aorta and mesenteric artery were dissected, fixed in 4% paraformaldehyde for 24 h and embedded in paraffin. Sections were deparaffinized, rehydrated and microwaved in citrate buffer for antigen retrieval. Sections were successively incubated in endogenous peroxidase and alkaline phosphatase block buffer (Dako, Glostrup, Denmark), protein block buffer and primary antibodies, which were incubated with the sections overnight at 4°C. After rinsing in wash buffer, sections were incubated with labelled polymer-horseradish peroxidase anti-mouse or anti-rabbit antibodies and 3,3'-diaminobenzidine (DAB) chromogen as described previously (Ding et al., 2016) . After a final wash, the sections were counterstained with haematoxylin.
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data were expressed as mean values ± SD. Distribution normality was assessed with the GraphPad Prism 5 analysis software (La Jolla, CA, USA), and all data were found to be normally distributed. Differences between groups were evaluated for significant differences using the Student's t-test for unpaired data or the one-way ANOVA with Bonferroni's post hoc test. All other results were analysed using a two-tailed Student's t-test for comparison between two groups. Values of P < 0.05 were considered significant.
Materials
Antibodies against total AMPKα, AMPKα1, AMPKα2, phospho-AMPKα (T172; 40H9, 2535), phospho-eukaryotic translation initiation factor 2α (eIF2α) and phosphophospholamban (S16/T17; 8496) were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies against spliced X-box binding protein-1 (XBP1s) were obtained from Biolegend (San Diego, CA, USA). Antibodies against Lys-Asp-Glu-Leu (KDEL) were obtained from Enzo Life Sciences (Farmingdale, NY). Antibodies against phospholamban (PLB) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Osmotic minipumps were purchased from Alzet (Palo Alto, CA, USA). Tauroursodeoxycholic acid (TUDCA) and Compound C were from Calbiochem (San Diego, CA, USA). AICAR was purchased from Toronto Research Chemicals, Inc. (Toronto, Canada). All other chemicals, unless otherwise specified, were purchased from Sigma-Aldrich (St. Louis, MO).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
Metformin reduces Ang II-induced hypertension in C57BL/6J mice
The model of Ang II-induced hypertension reproduces key features of human essential hypertension (Te Riet et al., 2015) . We first evaluated the effect of Ang II infusion (0.8 μg·g À1 ·day À1 for 14 days) on systolic (sBP) and diastolic BP (dBP) in mice. In line with previous reports (Liang et al., 2013) , Ang II infusion caused a marked increase in both sBP and dBP in adult C57BL/6J wild-type (WT) mice compared with the vehicle (saline) infusion ( Figure 1A -C).
Figure 1
Metformin attenuates Ang II-induced high BP in mice. (A-C) Effects of metformin (Met) on sBP (A), dBP (B) and mBP (C) in Ang II-infused WT (C57BL/6J) mice. n = 12-16 in each group. *P < 0.05, significantly different from vehicle (Veh). †P < 0.05, significantly different from Ang II; two-way ANOVA for repeated measures and Bonferroni post hoc test. Con, control.
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Interestingly, metformin treatment did not alter the BP in vehicle-infused mice, but did reduce sBP and dBP in Ang II-infused mice.
Ang II induces ER stress in mice and hVSMCs ER stress contributes to vascular smooth muscle contractility and high BP (Liang et al., 2013) . Therefore, we next investigated whether Ang II infusion causes ER stress in the aorta. Immunohistochemical staining for three wellcharacterized ER stress biomarkers [phosphorylated eIF2α (p-eIF2α), XBP1s and KDEL; Zode et al., 2011] in the aortic media area from Ang II-infused mice was stronger than that in aortas from vehicle-treated mice ( Figure 2A) . Furthermore, the Immunohistochemical staining for peIF2α and glucose-regulated protein 78 kDa (Grp78) in the media area of the mesenteric artery, a resistance vessel, from Ang II-infused mice was stronger than that from vehicletreated mice ( Figure 2B ). These results imply that ER stress in the aortic wall and resistance vessels may be associated with Ang II-induced hypertension in vivo. We next investigated whether Ang II induces ER stress in cultured hVSMCs in vitro. As depicted in Figure 2C , the protein expression of three markers of ER stress, XBP1s, Grp78 and p-eIF2α, was induced by Ang II in a dose-dependent manner, peaking at 5 μM Ang II. Furthermore, the expression of ER stress biomarkers was also increased by Ang II in a time-dependent manner, with observed increases after only 1 h Ang II exposure and a peak at 4 h treatment ( Figure 2D ). Intriguingly, TUDCA, a chemical chaperone that inhibits ER stress (Ben Mosbah et al., 2010) , markedly decreased the Ang II-induced increase in these three ER stress markers in hVSMCs ( Figure 2E ), suggesting that ER stress in VSMCs is induced by Ang II.
Metformin eliminates Ang II-induced ER stress in hVSMCs
We demonstrated previously that AMPK is a physiological suppressor of aberrant ER stress in endothelial cells (Dong et al., 2010a) . Here, we investigated whether Ang II-induced ER stress was dependent on AMPK inhibition in VSMCs. As shown in Figure 3A , low concentrations (0.1-1 μM) of Ang II led to minor activation of AMPK, whereas high concentrations (5 μM) of Ang II inhibited AMPKα phosphorylation in VSMCs. These data suggest that AMPK inactivation may contribute to Ang II-induced ER stress in hVSMCs ( Figure 2B ). We next determined whether AMPK activation inhibits ER stress in hVSMCs. Metformin, a wellknown AMPK activator (Zou et al., 2004) , dose-dependently enhanced AMPK phosphorylation ( Figure 3B ), indicating AMPK activation in VSMCs (Zhang et al., 2008) . Furthermore, metformin pretreatment decreased the ER stress biomarkers induced by the ER stress inducer tunicamycin ( Figure 3C ). As expected, treatment of hVSMCs with Ang II significantly enhanced ER stress as shown by increased levels of p-eIF2α, KDEL and XBP1s. Importantly, metformin treatment reversed the inhibition of AMPK by Ang II and consequently ameliorated the ER stress that was induced by Ang II ( Figure 3D ). Furthermore, Ang II treatment significantly elevated the cytosolic Ca 2+ ( Figure 3E ) concomitant with a reduction of Ca 2+ in the ER ( Figure 3F ). Pretreatment with metformin substantially decreased this Ang II-induced cytosolic Ca 2+ elevation, whereas metformin pretreatment increased the ER Ca 2+ levels that were reduced by Ang II ( Figure 3F ).
AMPK inactivation induces ER stress in hVSMCs
We next tested the effect of AMPK inactivation on ER stress. Compound C, a widely used AMPK inhibitor (Jin et al., 2009) , clearly increased the levels of ER stress biomarkers and further enhanced the Ang II-mediated ER stress in hVSMCs ( Figure 4A, B) . AMPKα1 knockdown in hVSMCs by AMPKα1-specific siRNA led to a modest increase in ER stress. However, AMPKα2 knockdown by AMPKα2-specific siRNA markedly induced ER stress as shown by increased expression of p-eIF2α, protein disulfide isomerase and XBP1s, compared with levels following treatment with scrambled siRNA ( Figure 4C ). Furthermore, ER stress in VSMCs isolated from AMPKα2 À/À mice was greater than that in VSMCs isolated from either AMPKα1 À/À or WT mice ( Figure 4D ). These results suggest that AMPKα2 is the critical AMPKα isoform that regulates ER stress in VSMCs and that AMPKα2 plays a more important role than AMPKα1 in regulating Ang II-induced hypertension in mice.
Inhibition of Ang II-induced ER stress by metformin is dependent on AMPKα2
We next investigated whether the protective mechanism of metformin is dependent on AMPKα2. As shown in Figure 4 E, AMPKα2 siRNA, but not scrambled siRNA, resulted in ER stress in hVSMCs, in agreement with observations in AMPKα2 À/À mVSMCs (Liang et al., 2013) . Furthermore, metformin ameliorated the Ang II-induced ER stress in scrambled siRNA-transfected hVSMCs but not in AMPKα2 siRNA-transfected hVSMCs ( Figure 4E ), suggesting that AMPKα2 is required for metformin alleviation of Ang IIinduced ER stress.
PLB phosphorylation is required for metformin inhibition of Ang II-induced ER stress
Elevation of intracellular Ca 2+ is a common mechanism involved in aberrant activation of ER stress and such changes of intracellular Ca 2+ is regulated through the activity of sarcoplasmic/ER Ca 2+ -ATPase (SERCA) (Dong et al., 2010a) . PLB in its non-phosphorylated form interacts with SERCA and inhibits its activity (Chen et al., 2007) ; however, upon PLB phosphorylation, SERCA functions normally and maintains ER Ca 2+ levels (Koss and Kranias, 1996) . Therefore, we next investigated the relevance of PLB to the inhibition by metformin of Ang II-mediated ER stress. Ang II dose-dependently decreased phosphorylation of PLB but did not affect total PLB protein levels ( Figure 5A ), while metformin restored PLB phosphorylation that had been blunted by Ang II treatment ( Figure 5B ). Furthermore, AMPKα2 silencing blocked the metformin-induced inhibition of Ang II-disrupted PLB phosphorylation ( Figure 5C ). Additionally, metformin suppressed Ang II-induced ER stress in control, scrambled siRNA-transfected hVSMCs but not in PLB siRNAtransfected hVSMCs ( Figure 5D ), indicating that PLB is required for suppression of Ang II-dependent ER stress by metformin.
AMPKα2 is required for metformin alleviation of Ang II-induced hypertension in mice
In line with previous reports (Wang et al., 2011; Liang et al., 2013) , the sBP, dBP and mean BP (mBP) in AMPKα2 À/À mice 
Discussion
In the present study, we demonstrated that Ang II-induced aberrant ER stress in VSMCs contributes to the elevation of BP and that metformin lowers this Ang II-induced high BP Metformin relieves hypertension by AMPK activation BJP via AMPKα2 activation-induced suppression of ER stress in VSMCs in mice. Mechanistically, metformin-mediated AMPK activation promotes the phosphorylation of PLB, which ultimately restores cellular calcium homeostasis mediated by SERCA activation, inhibits ER stress and alleviates Ang IIinduced hypertension in mice ( Figure 6E ). Elevated ER stress plays critical roles in the development and progression of cardiovascular diseases, including atherosclerotic plaque rupture (Saksi et al., 2014) , coronary artery disease and diabetic cardiomyopathy (Yang et al., 2015b) . Emerging evidence from humans (Du et al., 2017) as well as animal models indicates that enhanced ER stress is an important contributor to the development of hypertension (Hasty and Harrison, 2012; Liang et al., 2013) . For example, prolonged ER stress in the rostral ventrolateral medulla contributes to oxidative stress-associated neurogenic hypertension in spontaneously hypertensive rats (Chao et al., 2013) , and accordingly, the ER stress inhibitor TUDCA decreases sBP in the spontaneously hypertensive rats (Choi et al., 2016) . 4-Phenylbutyric acid (4-PBA), which is an ER stress inhibitor that is structurally unrelated to TUDCA, also lowers monocrotaline-induced pulmonary artery pressure in Figure 4 Metformin (Met) inhibition of Ang II-induced ER stress is dependent on AMPKα2 (a2) activation. (A) Effects of Compound C (Comp C), a known AMPK inhibitor, on ER stress after incubation for the indicated times. Representative blots from four independent experiments are shown. For each panel, the quantitated data from these experiments are shown. n = 5, *P < 0.05, significantly different from vehicle (Veh). (B) Effects of Comp C on Ang II-induced ER stress biomarkers. The blot is a representative of five blots from five individual experiments. n = 5, *P < 0.05, significantly different from Veh. †P < 0.05, significantly different from Veh/Ang II. (C) Effects of AMPKα2 knockdown on ER stress biomarkers in hVSMCs. The blot is a representative of five experiments. n = 5, *P < 0.05, significantly different from scrambled (Scr) siRNA. (D) The effects of AMPKα2 knockout in mVSMCs on ER stress biomarkers. The blot is a representative of four blots from four independent experiments. n = 5, *P < 0.05, significantly different from WT. (E) AMPKα2 is required for metformin inhibition on Ang II-induced ER stress in hVSMCs. Representative blots from three independent experiments are shown. n = 5, *P < 0.05, significantly different from Scr siRNA. †P < 0.05, significantly different from Scr siRNA/Ang II. #P < 0.05, significantly different from Scr siRNA/Ang II + Met. PDI, protein disulfide isomerase; α1, AMPKα1.
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male Wistar rats (Wu et al., 2016) . Furthermore, ER stress may be responsible for obesity-induced hypertension. Importantly, the main finding of the present work is that ER stress, mediated by AMPK inhibition, in VSMCs is a major cause underlying Ang II-dependent hypertension. We also demonstrated that the effect of metformin on suppression of ER stress in VSMCs is responsible for its BP-lowering effect. Thus, metformin alleviates Ang II-dependent hypertension via reduction of ER stress mediated by activation of AMPK. In agreement with these conclusions, we have demonstrated that AMPKα2 deletion promoted ER stress in the mouse aorta (Liang et al., 2013) . As Ang II-inhibited AMPK activation ( Figure 3A) and AMPK activation by metformin ( Figure 3B ) decreased Ang II-mediated ER stress in VSMCs ( Figure 3D ), Ang II-triggered ER stress may occur via AMPK inhibition. This finding is consistent with our previous study which demonstrated that AMPK acted as a physiological suppressor of ER stress by maintaining SERCA activity and intracellular Ca 2+ homeostasis in endothelial cells (Dong et al., 2010a) .
In addition, AMPK activation by irisin, a polypeptide containing 112 amino acids, secreted mainly by skeletal muscle cells during exercise, has been shown to lower BP in spontaneously hypertensive rats by improving NO bioactivity and endothelial cell function (Fu et al., 2016a) . This has been mechanistically attributed to the higher NO release by enhancing the phosphorylation and activation of endothelial NOS (eNOS) at Ser 1177 and Ser 633 (Chen et al., 2009; Zhang et al., 2009b) and by blocking NO inactivation by reactive oxygen species (Deng et al., 2010) . Indeed, a recent study demonstrates that the endothelium-specific AMPKα2 knockout mice have normotensive phenotype and endothelium-specific AMPKα1 knockout mice are hypertensive (Enkhjargal et al., 2014) , although the level of ER stress of these mice was not investigated. Taken together, ER stress-mediated endothelial dysfunction associated with eNOS uncoupling or endothelial oxidative stress might also be a critical trigger for the development of high BP (Cheang et al., 2014; Galan et al., 2014) . Further study on a causative effect of AMPK deletion-induced ER stress in VSMCs and BP elevation is needed. In addition, the ER stress suppressors, 4-phenylbutyric acid (4-PBA) (Tabas, 2010) or TUDCA, lower Ang II-elevated BP (Young et al., 2012; Liang et al., 2013) . Although metformin alone did not alter the BP in either WT or AMPKα2 À/À mice under normal conditions, metformin effectively normalized Ang II-elevated BP in WT mice but not in AMPKα2 À/À mice ( Figure 6A-C) . However, the non-FDA-approved drug AICAR ameliorates Ang II-increased BP in AMPKα2 À/À mice ( Figure 6 D), which may be due to the ER stress reduction and recovery of endothelial function (Dong et al., 2010b; Li et al., 2015) . These data suggest that the AMPKα2 isoform is required for maintaining normal BP and is involved in metformin alleviation of Ang II-induced hypertension. These results are in line with the notion that AMPKα2 is esssential for the BPlowering effects of resveratrol in deoxycorticosterone acetate-salt hypertensive mice (Sun et al., 2015) . Together, these results offer a possible explanation for the lack of effects of metformin on BP reduction in obese hypertensive patients (He et al., 2012) . Indeed, obesity is known to decrease or inhibit AMPKα in animals (Decleves et al., 2011; Davies et al., 2014; Fu et al., 2016b) and patients (Xu et al., 2012) . In addition, metformin may have no effect on high BP in the absence of ER stress or in cases of hypertension with normal AMPK activity. Thus, metformin only exerts its role in lowering BP under conditions where AMPKα2 is present, AMPK activity is inhibited and ER stress is elevated. These requirements offer a clear explanation of the paradoxical effects of metformin on hypertension in the clinic. PLB is the principal physiological inhibitor of SERCA (Koss and Kranias, 1996) , and phosphorylation of PLB at Ser 16 or Thr 17 enhances SERCA function to maintain ER calcium levels by decreasing the efficacy of PLB-mediated inhibition (Traister et al., 2014) . Recently, metformin was reported to enhance PLB degradation via autophagy in cardiomyocytes, exerting a protective function in hearts (Teng et al., 2015) . Furthermore, AMPK activation by A769662 increases PLB phosphorylation at Thr 17 in pooled femoral arteries (Schneider et al., 2015) . In agreement with these earlier data, we demonstrated that treatment of hVSMCs with Ang II reduced the level of phosphorylated PLB. The AMPKα2 isoform in VSMCs is required for metformin to block the inhibition, by Ang II, of PLB phosphorylation. Whether AMPKα2 directly or indirectly phosphorylates PLB, however, warrants further investigation. It remains to be determined whether other mechanisms are involved in the effects of metformin on lowering BP in humans. For example, metformin prevents hypertension in spontaneously hypertensive rats by reducing levels of asymmetric dimethylarginine (Tsai et al., 2014) . Metformin decreases NAD(P)H oxidase activity in mouse podocytes, leading to reduction of oxidative stress (Piwkowska et al., 2010) . Metformin restores endothelial function inhibited by changes in glucose levels, via AMPKdependent eNOS recoupling and reduction of p47-phox, a subunit of NADPH oxidase . Such reduction of oxidative stress and restoration of endothelial function contribute to the reduced BP in streptozotocin-induced diabetic rats (Majithiya and Balaraman, 2006) . In addition, metformin decreases Ang II-elevated BP in mice, which may occur via induction of urinary sodium excretion (Deji et al., 2012) . Alternatively, metformin may exert these effects via induction of ER stress in prostate cancer cells (Yang et al., 2015a) . Therefore, further investigation of these mechanisms is warranted in light of our findings.
In summary, our results indicate that aberrant ER stress accompanied the development of Ang II-mediated, high BP. Metformin inhibited Ang II-induced ER stress via an AMPKα2-PLB-SERCA pathway, and this pathway may provide a novel therapeutic target for treating hypertension.
